Continuous subcutaneous insulin infusion and sensor-augmented pump therapy in children and adolescents

Ivana Rabbone, Giulio Frontino, Riccardo Bonfanti

Research output: Contribution to journalArticlepeer-review

Abstract

Continuous subcutaneous insulin infusion (CSII) therapy is safe and effective in all age groups of type 1 diabetic patients. It may be elective therapy in neonatal diabetes and in preschool patients. Randomized trials in children and adolescents in CSII therapy have shown a significant improvement in treatment satisfaction without a substantial change in glycosylated hemoglobin A 1c (HbA 1c ). Elevated levels of HbA 1c not only at the start of CSII, but also during the follow-up, may be an important indicator of pump discontinuation. Sensor-augmented pump therapy (SAP) has a more beneficial effect in reducing HbA 1c values, hyperglycemic excursions, and glycemic variability in children and adolescents with type 1 diabetes. Data on the safety and feasibility of SAP in preschool children have also been published. The low glucose suspend (LGS) function and its evolution, the predictive LGS, represent semiautomated processes able to prevent severe hypoglycemic events and extreme glucose fluctuations also in type 1 diabetes children and adolescents.

Original languageEnglish
Pages (from-to)143-150
Number of pages8
JournalFrontiers in Diabetes
Volume24
DOIs
Publication statusPublished - 2015

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Internal Medicine

Fingerprint

Dive into the research topics of 'Continuous subcutaneous insulin infusion and sensor-augmented pump therapy in children and adolescents'. Together they form a unique fingerprint.

Cite this